Literature DB >> 23337420

GnRH agonist triggering: recent developments.

Shahar Kol1, Peter Humaidan.   

Abstract

The concept that a bolus of gonadotrophin-releasing hormone agonist (GnRHa) can replace human chorionic gonadotrophin(HCG) as a trigger of final oocyte maturation was introduced several years ago. Recent developments in the area strengthen this premise. GnRHa trigger offers important advantages, including virtually complete prevention of ovarian hyperstimulation syndrome(OHSS), the introduction of a surge of FSH in addition to the LH surge and finally the possibility to individualize luteal-phase supplementation based on ovarian response to stimulation. We maintain that the automatic HCG triggering concept should be challenged and that the GnRHa trigger is the way to move forward with thoughtful consideration of the needs, safety and comfort of our patients.
Copyright © 2012 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23337420     DOI: 10.1016/j.rbmo.2012.11.002

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  24 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome.

Authors:  Sherif A Hebisha; Banan A Aboelazm; H N Sallam
Journal:  J Obstet Gynaecol India       Date:  2016-11-29

3.  Hypothalamic gonadotropin-releasing hormone (GnRH) receptor neurons fire in synchrony with the female reproductive cycle.

Authors:  Christian Schauer; Tong Tong; Hugues Petitjean; Thomas Blum; Sophie Peron; Oliver Mai; Frank Schmitz; Ulrich Boehm; Trese Leinders-Zufall
Journal:  J Neurophysiol       Date:  2015-06-10       Impact factor: 2.714

4.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Anuja Dokras
Journal:  Fertil Steril       Date:  2014-11-06       Impact factor: 7.329

Review 6.  Freeze-all policy: is it time for that?

Authors:  Matheus Roque
Journal:  J Assist Reprod Genet       Date:  2014-11-27       Impact factor: 3.412

7.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 8.  Prevention of Ovarian Hyperstimulation Syndrome: A Review.

Authors:  Vinayak Smith; Tiki Osianlis; Beverley Vollenhoven
Journal:  Obstet Gynecol Int       Date:  2015-05-14

9.  What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?

Authors:  Jure Knez; Borut Kovačič; Maruška Medved; Veljko Vlaisavljević
Journal:  Reprod Biol Endocrinol       Date:  2015-06-10       Impact factor: 5.211

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.